Le Lézard
Classified in: Health
Subjects: SVY, BLK, TRI, DEI

American Lung Association Campaign Aims to Address Lack of Diversity in Clinical Trials, Improve Lung Cancer Care for Black Americans


CHICAGO, May 17, 2023 /PRNewswire/ -- The lung cancer five-year survival rate has increased by nearly 40% in the past decade. Unfortunately, this progress has not been shared equally. Black Americans with lung cancer are less likely to be diagnosed at an early stage, less likely to receive surgical treatment, and less likely to receive any treatment at all compared to white Americans. That's why the American Lung Association is expanding its work through the Awareness, Trust and Action program to increase awareness amongst Black Americans about clinical trials and encourage them to speak with their healthcare provider about their treatment options.

Lung cancer research is moving at a rapid pace, and clinical trials are critical to advancing promising lung cancer treatments. Clinical trials are highly monitored research studies that can test many things like how to prevent a disease, new ways to detect or diagnose a disease or new ways to treat a disease. Sometimes the most appropriate treatment option for a lung cancer patient is through a clinical trial. 

"We are facing an issue in cancer care in this country. Black Americans are underrepresented in clinical research, so I am working with the American Lung Association to fix that," said Danielle Mitchell, Founder and CEO of Black Women in Clinical Research. "I started my career as a clinical research coordinator because my grandmother had cancer. I saw the lack of diversity in clinical trials, and I have set out to change that because representation matters."

This underrepresentation happens for many reasons, with one of them being the long-standing history of racial bias in healthcare, which impacts access to care and trust in providers. It is important to enroll a diverse group of people in clinical trials so researchers can understand the effects of potential treatment methods on the different patient populations.

The American Lung Association is expanding its Awareness, Trust and Action campaign, which initially launched in 2022, to:

Learn more at Lung.org/trials-and-you.

Support for this project provided in part by Daiichi Sankyo, Genentech, Merk, Novartis and Novocure.

The Lung Association is committed to diversity, equity and inclusion (DEI) as core values. Our vision of a world free of lung disease includes all people, regardless of skin color, race, ethnicity, gender identity, creed, age, ability, sexual orientation, national origin, education, language or socio-economic status. Given the disproportionate impact of lung disease on historically underserved communities, the Lung Association embraces diversity as a moral and mission-driven imperative. This commitment governs all activities of the Lung Association, including policies and guidelines, procedures, programs, personnel practices and resource development to ensure that the diversity of the communities we serve?including but not limited to racial, ethnic and gender diversity?are reflected in our volunteers and staff. 

About the American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research. The work of the American Lung Association is focused on four strategic imperatives: to defeat lung cancer; to champion clean air for all; to improve the quality of life for those with lung disease and their families; and to create a tobacco-free future. For more information about the American Lung Association, a holder of the coveted 4-star rating from Charity Navigator and a Platinum-Level GuideStar Member, or to support the work it does, call 1-800-LUNGUSA (1-800-586-4872) or visit: Lung.org.

American Lung Association ? 55 W. Wacker Drive, Suite 1150 ? Chicago, IL 60601
1331 Pennsylvania Ave. NW, Ste. 1425 North ? Washington, D.C. 20004
1-800-LUNGUSA (1-800-586-4872) Lung.org

CONTACT: Jill Dale  |  American Lung Association
P: 312-801-7629E: [email protected]

SOURCE American Lung Association


These press releases may also interest you

at 01:30
PARIS, FRANCE, 2 May 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, announced today the appointment of Keira Driansky as EVP, President of North America, effective May 13, 2024. She will serve on the...

at 01:00
Management Report1 Q1 2024 highlights Strong performance in Perfumery & Beauty on good demand developmentGood performance in Taste, Texture & Health underpinned by market recoveryHealth, Nutrition & Care was soft, with improving momentum by end of...

at 00:01
Today, the Conference on Jewish Material Claims Against Germany (Claims Conference) launched a new digital campaign, #CancelHate. The campaign features Holocaust survivors reading Holocaust denial posts from across social media platforms. Each post...

at 00:00
With over four decades of nursing experience under her belt, Sherry Shaffer Ratajczak has witnessed firsthand the dedication of her colleagues in patient care. Yet, she observed a common misunderstanding: many are unaware of the extensive knowledge...

1 mai 2024
Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto's favor on multiple grounds. This decision reverses the initial verdict of $185 million in its entirety and...

1 mai 2024
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Poseida Therapeutics, Inc.  today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, "Xyphos") and Poseida have entered into a...



News published on and distributed by: